Mesenchymal Stromal Cell Patents: Leaders & White Space 2026
Mesenchymal Stromal Cell Product Patents: Concentration, Trends and Open Claim Space
Top 5 assignees hold 46.1% of all 269 records in scope, and the top 10 combined reach 70.6% — concentration builds fast past the leader. Filings climbed to a peak of 66 records in 2019, then fell across the early 2020s — down -51% from 39 records in 2021 to 19 in 2024, the most recent year the trend can be read as complete given publication lag.
- 1MACROGENICS INC35
- 2INIMMUNE CORP32
- 3COMBANGIO INC26
- 4COMPUGEN16
- 5TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH15
See the full mesenchymal stromal cell products analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Frequently asked questions
Who holds the most patents on mesenchymal stromal cell products?
One assignee leads with 35 of the 269 records in this dataset, roughly double the fifth-placed filer’s 15. The top 5 assignees combined hold 46.1% of all records, and the top 10 hold 70.6%, so competitive filing analysis in this space should focus on that group of ten rather than the full 78-company ranking. Despite its lead, the top assignee shows zero filings in the most recent recorded year, which may reflect a genuine slowdown or simply publication lag catching up.
Is patent filing activity in MSC product technology growing or shrinking?
Filings peaked at 66 records in 2019 and have declined since, falling -51% from 39 records in 2021 to 19 in 2024, the last year the trend can be read as complete. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and should not be read as confirming further decline. The honest read is a field that has cooled from a 2019 peak, not one currently accelerating.
What technology areas dominate MSC product patent claims?
A61K medicinal-preparation claims appear in 99.3% of the 269 records, making formulation claims essentially universal in this space. A61P therapeutic-activity claims (55.8%) and C12N genetic-engineering claims (50.6%) each cover roughly half the records, while testing-oriented classes like G01N (4.8%) and C12Q (3.0%) are comparatively sparse. That gap suggests potency-assay and identity-testing methods carry less claim density than the product and formulation side.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Mesenchymal Stromal Cell Products covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.